{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:36:41Z","timestamp":1785458201678,"version":"3.56.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T00:00:00Z","timestamp":1643328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010413","name":"Fundaci\u00f3n Ren\u00e9 Bar\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010413","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Programa Bec.Ar Fundacion Bunge y Born Fundacion Williams"},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA196266"],"award-info":[{"award-number":["R01CA196266"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R21AI135851"],"award-info":[{"award-number":["R21AI135851"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Five New World mammarenaviruses (NWMs) cause life-threatening hemorrhagic fever (HF). Cellular entry by these viruses is mediated by human transferrin receptor 1 (hTfR1). Here, we demonstrate that an antibody (ch128.1\/IgG1) which binds the apical domain of hTfR1, potently inhibits infection of attenuated and pathogenic NWMs in vitro. Computational docking of the antibody Fab crystal structure onto the known structure of hTfR1 shows an overlapping receptor-binding region shared by the Fab and the viral envelope glycoprotein GP1 subunit that binds hTfR1, and we demonstrate competitive inhibition of NWM GP1 binding by ch128.1\/IgG1 as the principal mechanism of action. Importantly, ch128.1\/IgG1 protects hTfR1-expressing transgenic mice against lethal NWM challenge. Additionally, the antibody is well-tolerated and only partially reduces ferritin uptake. Our findings provide the basis for the development of a novel, host receptor-targeted antibody therapeutic broadly applicable to the treatment of HF of NWM etiology.<\/jats:p>","DOI":"10.1038\/s41467-021-27949-3","type":"journal-article","created":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T11:03:34Z","timestamp":1643367814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections"],"prefix":"10.1038","volume":"13","author":[{"given":"Brady T.","family":"Hickerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8277-9702","authenticated-orcid":false,"given":"Tracy R.","family":"Daniels-Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Payes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-7597","authenticated-orcid":false,"given":"Lars E.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre V.","family":"Candelaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sefing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3220-8290","authenticated-orcid":false,"given":"Samantha","family":"Zink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ziegenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7937-3920","authenticated-orcid":false,"given":"Jonathan","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-3564","authenticated-orcid":false,"given":"Gustavo","family":"Helguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel L.","family":"Penichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9113-2575","authenticated-orcid":false,"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,28]]},"reference":[{"key":"27949_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.mib.2008.06.001","volume":"11","author":"RN Charrel","year":"2008","unstructured":"Charrel, R. N., de Lamballerie, X. & Emonet, S. Phylogeny of the genus Arenavirus. Curr. Opin. Microbiol. 11, 362\u2013368 (2008).","journal-title":"Curr. Opin. Microbiol."},{"key":"27949_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-virology-101416-042001","volume":"4","author":"N Sarute","year":"2017","unstructured":"Sarute, N. & Ross, S. R. New World arenavirus biology. Annu. Rev. Virol. 4, 141\u2013158 (2017).","journal-title":"Annu. Rev. Virol."},{"key":"27949_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2007.10.010","volume":"78","author":"DA Enria","year":"2008","unstructured":"Enria, D. A., Briggiler, A. M. & Sanchez, Z. Treatment of Argentine hemorrhagic fever. Antiviral Res. 78, 132\u2013139 (2008).","journal-title":"Antiviral Res"},{"key":"27949_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.coviro.2014.02.007","volume":"5","author":"M Patterson","year":"2014","unstructured":"Patterson, M., Grant, A. & Paessler, S. Epidemiology and pathogenesis of Bolivian hemorrhagic fever. Curr. Opin. Virol. 5, 82\u201390 (2014).","journal-title":"Curr. Opin. Virol."},{"key":"27949_CR5","unstructured":"NIAID. NIAID Category A, B, and C Priority Pathogens https:\/\/www.niaid.nih.gov\/research\/emerging-infectious-diseases-pathogens (2016)."},{"key":"27949_CR6","unstructured":"CDC. Bioterrorism Agents\/Diseases https:\/\/emergency.cdc.gov\/agent\/agentlist-category.asp (2018)."},{"key":"27949_CR7","unstructured":"WHO. 2018 Annual review of diseases prioritized under the Research and Development Blueprint https:\/\/www.who.int\/news-room\/events\/detail\/2018\/02\/06\/default-calendar\/2018-annual-review-of-diseases-prioritized-under-the-research-anddevelopment-blueprint (2018)."},{"key":"27949_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature05539","volume":"446","author":"SR Radoshitzky","year":"2007","unstructured":"Radoshitzky, S. R. et al. Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses. Nature 446, 92\u201396 (2007).","journal-title":"Nature"},{"key":"27949_CR9","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1073\/pnas.0709254105","volume":"105","author":"SR Radoshitzky","year":"2008","unstructured":"Radoshitzky, S. R. et al. Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses. Proc. Natl. Acad. Sci. U.S.A. 105, 2664\u20132669 (2008).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"27949_CR10","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1128\/JVI.06397-11","volume":"86","author":"G Helguera","year":"2012","unstructured":"Helguera, G. et al. An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic fever arenaviruses. J. Virol. 86, 4024\u20134028 (2012).","journal-title":"J. Virol."},{"key":"27949_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","volume":"133","author":"H Kawabata","year":"2019","unstructured":"Kawabata, H. Transferrin and transferrin receptors update. Free Radic. Biol. Med. 133, 46\u201354 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"27949_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","volume":"121","author":"TR Daniels","year":"2006","unstructured":"Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G. & Penichet, M. L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121, 144\u2013158 (2006).","journal-title":"Clin. Immunol."},{"key":"27949_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/47417","volume":"403","author":"MJ Bennett","year":"2000","unstructured":"Bennett, M. J., Lebron, J. A. & Bjorkman, P. J. Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature. 403, 46\u201353 (2000).","journal-title":"Nature"},{"key":"27949_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09098-w","volume":"10","author":"LC Montemiglio","year":"2019","unstructured":"Montemiglio, L. C. et al. Cryo-EM structure of the human ferritin-transferrin receptor 1 complex. Nat. Commun. 10, 1121 (2019).","journal-title":"Nat. Commun."},{"key":"27949_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0092-8674(04)00130-8","volume":"116","author":"Y Cheng","year":"2004","unstructured":"Cheng, Y., Zak, O., Aisen, P., Harrison, S. C. & Walz, T. Structure of the human transferrin receptor-transferrin complex. Cell. 116, 565\u2013576 (2004).","journal-title":"Cell"},{"key":"27949_CR16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nsmb.1772","volume":"17","author":"J Abraham","year":"2010","unstructured":"Abraham, J., Corbett, K. D., Farzan, M., Choe, H. & Harrison, S. C. Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses. Nat. Struct. Mol. Biol. 17, 438\u2013444 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"27949_CR17","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1128\/JVI.01112-14","volume":"88","author":"M Zong","year":"2014","unstructured":"Zong, M., Fofana, I. & Choe, H. Human and host species transferrin receptor 1 use by North American arenaviruses. J. Virol. 88, 9418\u20139428 (2014).","journal-title":"J. Virol."},{"key":"27949_CR18","first-page":"793257","volume":"2015","author":"JW Golden","year":"2015","unstructured":"Golden, J. W., Hammerbeck, C. D., Mucker, E. M. & Brocato, R. L. Animal models for the study of rodent-borne hemorrhagic fever viruses: arenaviruses and hantaviruses. Biomed. Res. Int. 2015, 793257 (2015).","journal-title":"Biomed. Res. Int."},{"key":"27949_CR19","first-page":"493","volume":"52","author":"PA Webb","year":"1975","unstructured":"Webb, P. A., Justines, G. & Johnson, K. M. Infection of wild and laboratory animals with Machupo and Latino viruses. Bull. World Health Organ. 52, 493\u2013499 (1975).","journal-title":"Bull. World Health Organ"},{"key":"27949_CR20","doi-asserted-by":"publisher","first-page":"e55352","DOI":"10.7554\/eLife.55352","volume":"9","author":"BT Hickerson","year":"2020","unstructured":"Hickerson, B. T. et al. Type I interferon underlies severe disease associated with Junin virus infection in mice. Elife. 9, e55352 (2020).","journal-title":"Elife"},{"key":"27949_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2007.08.020","volume":"124","author":"JA Rodriguez","year":"2007","unstructured":"Rodriguez, J. A. et al. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor. J. Control. Release. 124, 35\u201342 (2007).","journal-title":"J. Control. Release"},{"key":"27949_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nprot.2016.169","volume":"12","author":"D Kozakov","year":"2017","unstructured":"Kozakov, D. et al. The ClusPro web server for protein-protein docking. Nat. Protoc. 12, 255\u2013278 (2017).","journal-title":"Nat. Protoc."},{"key":"27949_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/bioinformatics\/btq007","volume":"26","author":"S Chaudhury","year":"2010","unstructured":"Chaudhury, S., Lyskov, S. & Gray, J. J. PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta. Bioinformatics. 26, 689\u2013691 (2010).","journal-title":"Bioinformatics"},{"key":"27949_CR24","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1021\/acs.biochem.6b00444","volume":"55","author":"BJ Bender","year":"2016","unstructured":"Bender, B. J. et al. Protocols for molecular modeling with Rosetta3 and RosettaScripts. Biochemistry. 55, 4748\u20134763 (2016).","journal-title":"Biochemistry"},{"key":"27949_CR25","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1084\/jem.175.6.1501","volume":"175","author":"PM Lansdorp","year":"1992","unstructured":"Lansdorp, P. M. & Dragowska, W. Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow. J. Exp. Med. 175, 1501\u20131509 (1992).","journal-title":"J. Exp. Med."},{"key":"27949_CR26","doi-asserted-by":"publisher","first-page":"607692","DOI":"10.3389\/fimmu.2021.607692","volume":"12","author":"PV Candelaria","year":"2021","unstructured":"Candelaria, P. V., Leoh, L. S., Penichet, M. L. & Daniels-Wells, T. R. Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents. Front. Immunol. 12, 607692 (2021).","journal-title":"Front. Immunol."},{"key":"27949_CR27","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1097\/PAS.0b013e31821247a8","volume":"35","author":"HY Dong","year":"2011","unstructured":"Dong, H. Y., Wilkes, S. & Yang, H. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A. Am. J. Surg. Pathol. 35, 723\u2013732 (2011).","journal-title":"Am. J. Surg. Pathol."},{"key":"27949_CR28","doi-asserted-by":"crossref","unstructured":"Richard, C. & Verdier, F. Transferrin receptors in erythropoiesis. Int. J. Mol. Sci. 21, 9713 (2020).","DOI":"10.3390\/ijms21249713"},{"key":"27949_CR29","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1634\/stemcells.2007-0117","volume":"26","author":"S Knaan-Shanzer","year":"2008","unstructured":"Knaan-Shanzer, S. et al. Phenotypic and functional reversal within the early human hematopoietic compartment. Stem Cells. 26, 3210\u20133217 (2008).","journal-title":"Stem Cells"},{"key":"27949_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1600-0609.1997.tb01693.x","volume":"59","author":"S Gross","year":"1997","unstructured":"Gross, S. et al. Characterization and phenotypic analysis of differentiating CD34+ human bone marrow cells in liquid culture. Eur. J. Haematol. 59, 318\u2013326 (1997).","journal-title":"Eur. J. Haematol."},{"key":"27949_CR31","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.3109\/10428194.2011.596964","volume":"52","author":"JA Rodriguez","year":"2011","unstructured":"Rodriguez, J. A. et al. Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells. Leuk. Lymphoma. 52, 2169\u20132178 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"27949_CR32","doi-asserted-by":"publisher","first-page":"10777","DOI":"10.1073\/pnas.1301764110","volume":"110","author":"DN Martin","year":"2013","unstructured":"Martin, D. N. & Uprichard, S. L. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc. Natl. Acad. Sci. U.S.A. 110, 10777\u201310782 (2013).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"27949_CR33","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1073\/pnas.0913192107","volume":"107","author":"L Li","year":"2010","unstructured":"Li, L. et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc. Natl. Acad. Sci. U.S.A. 107, 3505\u20133510 (2010).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"27949_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1126\/science.286.5440.779","volume":"286","author":"CM Lawrence","year":"1999","unstructured":"Lawrence, C. M. et al. Crystal structure of the ectodomain of human transferrin receptor. Science. 286, 779\u2013782 (1999).","journal-title":"Science"},{"key":"27949_CR35","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3389\/fimmu.2017.01751","volume":"8","author":"JC Almagro","year":"2017","unstructured":"Almagro, J. C., Daniels-Wells, T. R., Perez-Tapia, S. M. & Penichet, M. L. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Front. Immunol. 8, 1751 (2017).","journal-title":"Front. Immunol."},{"key":"27949_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000479240","volume":"44","author":"A Kretschmer","year":"2017","unstructured":"Kretschmer, A., Schwanbeck, R., Valerius, T. & Rosner, T. Antibody isotypes for tumor immunotherapy. Transfus. Med. Hemother. 44, 320\u2013326 (2017).","journal-title":"Transfus. Med. Hemother."},{"key":"27949_CR37","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nri1837","volume":"6","author":"PJ Carter","year":"2006","unstructured":"Carter, P. J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343\u2013357 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"27949_CR38","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4161\/mabs.1.4.9122","volume":"1","author":"R Jefferis","year":"2009","unstructured":"Jefferis, R. & Lefranc, M. P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs. 1, 332\u2013338 (2009).","journal-title":"MAbs"},{"key":"27949_CR39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/0300985815588609","volume":"53","author":"TM Bell","year":"2016","unstructured":"Bell, T. M. et al. Pathogenesis of bolivian hemorrhagic fever in guinea pigs. Vet. Pathol. 53, 190\u2013199 (2016).","journal-title":"Vet. Pathol."},{"key":"27949_CR40","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4269\/ajtmh.2008.79.275","volume":"79","author":"NE Yun","year":"2008","unstructured":"Yun, N. E. et al. Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs. Am. J. Trop. Med. Hyg. 79, 275\u2013282 (2008).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"27949_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4269\/ajtmh.1996.55.81","volume":"55","author":"WC Hall","year":"1996","unstructured":"Hall, W. C., Geisbert, T. W., Huggins, J. W. & Jahrling, P. B. Experimental infection of guinea pigs with Venezuelan hemorrhagic fever virus (Guanarito): a model of human disease. Am. J. Trop. Med. Hyg. 55, 81\u201388 (1996).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"27949_CR42","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","volume":"6","author":"YJ Yu","year":"2014","unstructured":"Yu, Y. J. et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci. Transl. Med. 6, 261ra154 (2014).","journal-title":"Sci. Transl. Med."},{"key":"27949_CR43","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0140-6736(79)92335-3","volume":"2","author":"JI Maiztegui","year":"1979","unstructured":"Maiztegui, J. I., Fernandez, N. J. & de Damilano, A. J. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 2, 1216\u20131217 (1979).","journal-title":"Lancet"},{"key":"27949_CR44","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","volume":"10","author":"KO Saunders","year":"2019","unstructured":"Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).","journal-title":"Front. Immunol."},{"key":"27949_CR45","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/icb.2016.65","volume":"94","author":"AM Collins","year":"2016","unstructured":"Collins, A. M. IgG subclass co-expression brings harmony to the quartet model of murine IgG function. Immunol. Cell Biol. 94, 949\u2013954 (2016).","journal-title":"Immunol. Cell Biol."},{"key":"27949_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns, P. & Jonsson, F. Mouse and human FcR effector functions. Immunol. Rev. 268, 25\u201351 (2015).","journal-title":"Immunol. Rev."},{"key":"27949_CR47","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","volume":"189","author":"MB Overdijk","year":"2012","unstructured":"Overdijk, M. B. et al. Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189, 3430\u20133438 (2012).","journal-title":"J. Immunol."},{"key":"27949_CR48","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1126\/science.1118948","volume":"310","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn, F. & Ravetch, J. V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310, 1510\u20131512 (2005).","journal-title":"Science"},{"key":"27949_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.tiv.2012.10.006","volume":"27","author":"TR Daniels-Wells","year":"2013","unstructured":"Daniels-Wells, T. R. et al. Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1. Toxicol. In Vitro. 27, 220\u2013231 (2013).","journal-title":"Toxicol. In Vitro"},{"key":"27949_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ijc.2910320314","volume":"32","author":"R Taetle","year":"1983","unstructured":"Taetle, R., Honeysett, J. M. & Trowbridge, I. Effects of anti-transferrin receptor antibodies on growth of normal and malignant myeloid cells. Int. J. Cancer. 32, 343\u2013349 (1983).","journal-title":"Int. J. Cancer"},{"key":"27949_CR51","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1084\/jem.20091488","volume":"207","author":"C Callens","year":"2010","unstructured":"Callens, C. et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J. Exp. Med. 207, 731\u2013750 (2010).","journal-title":"J. Exp. Med."},{"key":"27949_CR52","first-page":"747","volume":"47","author":"CA Sauvage","year":"1987","unstructured":"Sauvage, C. A., Mendelsohn, J. C., Lesley, J. F. & Trowbridge, I. S. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. Cancer Res. 47, 747\u2013753 (1987).","journal-title":"Cancer Res"},{"key":"27949_CR53","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.bbrc.2017.02.039","volume":"485","author":"S Shimosaki","year":"2017","unstructured":"Shimosaki, S. et al. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia\/lymphoma. Biochem. Biophys. Res. Commun. 485, 144\u2013151 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"27949_CR54","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.1158\/1538-7445.AM2017-5586","volume":"77","author":"L Zhang","year":"2017","unstructured":"Zhang, L. et al. Abstract 5586: PPMX-T003, a fully human anti-TfR1 antibody with potent efficacy against hematologic malignancies. Cancer Res. 77, 5586 (2017).","journal-title":"Cancer Res"},{"key":"27949_CR55","doi-asserted-by":"publisher","first-page":"13089","DOI":"10.1073\/pnas.1105786108","volume":"108","author":"BE Eckenroth","year":"2011","unstructured":"Eckenroth, B. E., Steere, A. N., Chasteen, N. D., Everse, S. J. & Mason, A. B. How the binding of human transferrin primes the transferrin receptor potentiating iron release at endosomal pH. Proc. Natl. Acad. Sci. U.S.A. 108, 13089\u201313094 (2011).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"27949_CR56","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1006\/jmbi.2001.5048","volume":"313","author":"AP West Jr","year":"2001","unstructured":"West, A. P. Jr. et al. Mutational analysis of the transferrin receptor reveals overlapping HFE and transferrin binding sites. J. Mol. Biol. 313, 385\u2013397 (2001).","journal-title":"J. Mol. Biol."},{"key":"27949_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13924-6","volume":"11","author":"H Cohen-Dvashi","year":"2020","unstructured":"Cohen-Dvashi, H. et al. Rational design of universal immunotherapy for TfR1-tropic arenaviruses. Nat. Commun. 11, 67 (2020).","journal-title":"Nat. Commun."},{"key":"27949_CR58","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1038\/mtna.2016.32","volume":"5","author":"KE Maier","year":"2016","unstructured":"Maier, K. E. et al. A new transferrin receptor aptamer inhibits new world hemorrhagic fever mammarenavirus entry. Mol. Ther. Nucleic Acids. 5, e321 (2016).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"27949_CR59","doi-asserted-by":"publisher","first-page":"e0186820","DOI":"10.1128\/JVI.01868-20","volume":"95","author":"S Ferrero","year":"2021","unstructured":"Ferrero, S. et al. Antibody-based inhibition of pathogenic New World hemorrhagic fever mammarenaviruses by steric occlusion of the human transferrin receptor 1 apical domain. J. Virol. 95, e0186820 (2021).","journal-title":"J. Virol."},{"key":"27949_CR60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.antiviral.2017.07.019","volume":"145","author":"BB Gowen","year":"2017","unstructured":"Gowen, B. B. et al. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antiviral Res. 145, 131\u2013135 (2017).","journal-title":"Antiviral Res"},{"key":"27949_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04271-z","volume":"9","author":"LE Clark","year":"2018","unstructured":"Clark, L. E. et al. Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses. Nat. Commun. 9, 1884 (2018).","journal-title":"Nat. Commun."},{"key":"27949_CR62","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1073\/pnas.1600996113","volume":"113","author":"L Zeitlin","year":"2016","unstructured":"Zeitlin, L. et al. Monoclonal antibody therapy for Junin virus infection. Proc. Natl. Acad. Sci. U.S.A. 113, 4458\u20134463 (2016).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"27949_CR63","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1128\/JVI.02102-10","volume":"85","author":"SF Emonet","year":"2011","unstructured":"Emonet, S. F. et al. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J. Virol. 85, 1473\u20131483 (2011).","journal-title":"J. Virol."},{"key":"27949_CR64","first-page":"6295","volume":"50","author":"S White","year":"1990","unstructured":"White, S., Taetle, R., Seligman, P. A., Rutherford, M. & Trowbridge, I. S. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res. 50, 6295\u20136301 (1990).","journal-title":"Cancer Res"},{"key":"27949_CR65","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/CJI.0000000000000304","volume":"43","author":"TR Daniels-Wells","year":"2020","unstructured":"Daniels-Wells, T. R. et al. An IgG1 version of the anti-transferrin receptor 1 antibody ch128.1 shows significant antitumor activity against different xenograft models of multiple myeloma: a brief communication. J. Immunother. 43, 48\u201352 (2020).","journal-title":"J. Immunother."},{"key":"27949_CR66","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.4049\/jimmunol.1700787","volume":"200","author":"LS Leoh","year":"2018","unstructured":"Leoh, L. S. et al. Efficacy and mechanism of antitumor activity of an antibody targeting transferrin receptor 1 in mouse models of human multiple myeloma. J. Immunol. 200, 3485\u20133494 (2018).","journal-title":"J. Immunol."},{"key":"27949_CR67","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1084\/jem.173.4.1025","volume":"173","author":"MH Tao","year":"1991","unstructured":"Tao, M. H., Canfield, S. M. & Morrison, S. L. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J. Exp. Med. 173, 1025\u20131028 (1991).","journal-title":"J. Exp. Med."},{"key":"27949_CR68","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/CJI.0000000000000092","volume":"38","author":"TR Daniels-Wells","year":"2015","unstructured":"Daniels-Wells, T. R., Widney, D. P., Leoh, L. S., Martinez-Maza, O. & Penichet, M. L. Efficacy of an anti-transferrin receptor 1 antibody against aids-related non-hodgkin lymphoma: a brief communication. J. Immunother. 38, 307\u2013310 (2015).","journal-title":"J. Immunother."},{"key":"27949_CR69","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1128\/AAC.00356-07","volume":"51","author":"BB Gowen","year":"2007","unstructured":"Gowen, B. B. et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51, 3168\u20133176 (2007).","journal-title":"Antimicrob. Agents Chemother."},{"key":"27949_CR70","first-page":"493","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27, 493\u2013497 (1938).","journal-title":"Am. J. Hyg."},{"key":"27949_CR71","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1107\/S0907444906029799","volume":"62","author":"AR Aricescu","year":"2006","unstructured":"Aricescu, A. R., Lu, W. & Jones, E. Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243\u20131250 (2006).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"27949_CR72","doi-asserted-by":"publisher","unstructured":"Helguera, G. et al. Antigen binding fragment of ch128.1. World Wide Data Bank https:\/\/doi.org\/10.2210\/pdb6wla\/pdb (2020).","DOI":"10.2210\/pdb6wla\/pdb"},{"key":"27949_CR73","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"27949_CR74","unstructured":"BUSTER: Global Phasing Ltd., Cambridge, United Kingdom v. 2.10.4 (2017)."},{"key":"27949_CR75","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"27949_CR76","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/prot.21997","volume":"72","author":"D Kozakov","year":"2008","unstructured":"Kozakov, D., Schueler-Furman, O. & Vajda, S. Discrimination of near-native structures in protein-protein docking by testing the stability of local minima. Proteins. 72, 993\u20131004 (2008).","journal-title":"Proteins"},{"key":"27949_CR77","doi-asserted-by":"publisher","first-page":"W96","DOI":"10.1093\/nar\/gkh354","volume":"32","author":"SR Comeau","year":"2004","unstructured":"Comeau, S. R., Gatchell, D. W., Vajda, S. & Camacho, C. J. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res. 32, W96\u2013W99 (2004).","journal-title":"Nucleic Acids Res"},{"key":"27949_CR78","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/leu.2008.270","volume":"23","author":"E Ortiz-Sanchez","year":"2009","unstructured":"Ortiz-Sanchez, E. et al. Enhanced cytotoxicity of an anti-transferrin receptor IgG3-avidin fusion protein in combination with gambogic acid against human malignant hematopoietic cells: functional relevance of iron, the receptor, and reactive oxygen species. Leukemia. 23, 59\u201370 (2009).","journal-title":"Leukemia"},{"key":"27949_CR79","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1158\/1535-7163.MCT-07-0330","volume":"6","author":"TR Daniels","year":"2007","unstructured":"Daniels, T. R. et al. Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells. Mol. Cancer Ther. 6, 2995\u20133008 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"27949_CR80","doi-asserted-by":"publisher","unstructured":"Zink, S. Antibody-Antigen PyRosetta Docking. Zenodo https:\/\/doi.org\/10.5281\/zenodo.5753530 (2021).","DOI":"10.5281\/zenodo.5753530"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27949-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T16:14:53Z","timestamp":1669306493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27949-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,28]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["27949"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27949-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,28]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Manuel Penichet has a financial interest in Stellar Biosciences, Inc. The Regents of the University of California are in discussions with Stellar Biosciences to license a technology invented by Dr. Penichet to this firm. In addition, Dr. Penichet has a financial interest in Klyss Biotech, Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures complied with USDA guidelines and were conducted at the AAALAC-accredited laboratory animal research facilities at Utah State University under protocol #10034, approved by the Utah State University Institutional Animal Care and Use Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"558"}}